Latest Cardenolides Stories
OAKLAND, Calif., Nov.
We are advised by Kaiser Permanente that journalists and other readers should disregard the news release, Digoxin Associated With Higher Risk of Death and Hospitalization in Adults With Atrial Fibrillation
OAKLAND, Calif., Oct.
CARY, N.C., Feb.
WOODCLIFF LAKE, N.J., Jan. 16, 2014 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S.
A study published today in the European Heart Journal found no evidence that digoxin increases mortality in patients with atrial fibrillation (AF), the opposite of results just published by another group in the same journal analyzing the same data.
Researchers recently discovered that digoxin, a drug commonly utilized in heart disease treatments, could heighten the risk of death for patients who suffer from atrial fibrillation.
Digoxin, a drug that has been used worldwide for centuries to treat heart disease, is associated with a significant increase in deaths in patients with atrial fibrillation (AF).
An ancient heart drug that’s inspired the work of herbalists and poets for centuries may treat a condition that plagues millions of overstressed and overweight Americans today.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.